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Abstract 
The human Wilms tumour suppressor gene, WTl, encodes a zinc-finger protein which can function as a transcriptional activator or suppressor. 
This study reports the analysis of the human WTl gene promoter, and demonstrates that high levels of WTl expression lead to autosuppression 
of the WTl promoter. Deletion analyses of the promoter egion implicate sequences 5’ and 3’ of the transcriptional start site as being crucial in WTI 
autosuppression. Loss or alteration of this function of WTl may be important in tumourigenesis. 
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1. Introduction 
Wilms tumour is a paediatric renal malignancy affect- 
ing l/10,000 children, representing the most common 
abdominal solid tumour of childhood [l]. Cytogenetic 
analyses of the WAGR syndrome (Wilms tumour, anir- 
idia, genitourinary malformation and mental retarda- 
tion) identified a region on chromosome 1 1~13 as one of 
the loci of genes involved in these diseases [2,3]. Subse- 
quently, several groups cloned a Wilms tumour gene, 
WTl [4-61, which has been shown to undergo large ho- 
mozygous deletions as well as small intergenic deletions 
and point mutations [5-l 11. These studies strongly impli- 
cate loss of WTl function as an important factor in 
tumour development, and identify WTl as a putative 
tumour suppressor gene. 
The pattern of WTl gene expression in the condensing 
mesenchyme, renal vesicles and glomerular epithelium of 
developing kidney suggest hat WTl plays a role in kid- 
ney differentiation [12]. The structure of the WTl gene 
product shows a glutamine/proline-rich negatively 
charged amino-terminus characteristic of transcription- 
regulating regions of transcription factors, and a car- 
boxy-terminal region containing four zinc finger do- 
mains involved in DNA binding. The WTl protein is 
expressed as four isoforms arising from two alternative 
splice sites (I and II) in the gene [13,14]. Splice II occurs 
within the zinc finger domain, inserting or omitting three 
amino-acids (KTS) between zinc fingers 3 and 4. The 
WTl protein without KTS (WTl-KTS) specifically 
binds to the EGR (early growth response) consensus 
sequence, whereas WTl+KTS does not [15]. By binding 
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Abbreviations: IGFII, insulin-like growth factor II; PDGF-A, platelet- 
derived growth factor A; SSC, standard saline citrate; DMEM, Dul- 
becco’s modification of Eagle’s medium; bp, base-pairs; kb, kilobases. 
to the EGR sites in the promoter regions of genes such 
as IGFII and PDGF-A, WTl acts as a transcriptional 
repressor [16-191. More recent studies have shown that 
WTl can also activate transcription and bind a second 
DNA sequence motif comprising TCC repeats [20,21]. 
Thus WTl can negatively or positively regulate tran- 
scription. 
The human WTl gene promoter region has recently 
been characterized [22,23]. In view of the observations 
that tight and specific control of the WTl gene is impor- 
tant in normal kidney development, we have sought to 
define the basal WTl promoter unit, and to examine 
whether the WTl protein has the potential for self-regu- 
lation. As only about 10% of Wilms tumours show muta- 
tions of the coding region (reviewed in [24]), aberrant 
self-regulation may be a mechanism by which quantita- 
tive changes in WTl contribute to WTl dysfunction and 
tumour development. 
2. Materials and methods 
2.1. Cloning of WTI cDNA and genomic clones 
The WTl cDNA and WTl promoter region were cloned from a 
human foetal kidney cDNA library (Clontech) and a human B-cell 
genomic library (jlSha2001, kindly supplied by T.H. Rabbitts, MRC, 
Cambridge), respectively. For each library, Plaque screen filters (Du 
Pont) were prepared in situ from 1 x IO6 phage [25]. Filters were 
hybridized in 6 x SSC (1 x SSC = 0.15 M NaCl, 0.015 M sodium 
citrate), 5 x Denhardts solution, 0.5% SDS and 100 @ml salmon 
sperm DNA at 65°C. Washing was performed at high stringency 
(0.1 x SSC, 0.5% SDS, 65°C). For the cDNA library, a partial WTl 
cDNA obtained by PCR amplification was used as a probe. The DNA 
sequence of a full-length cDNA isolated from the cDNA library was 
determined by the dideoxy chain termination method [26], and a 700 
bp fragment from the 5’ terminus of the cDNA was used for probing 
the genomic library. Probes were radiolabelled with [cc-‘*P]dCTP 
(Amersham) according to the random primer method [27]. 
The full-length WTl cDNA was subcloned into pMEP4 (Invitrogen) 
to give the WTl eukaryoticexpression construct pMWT. The promoter 
region of the WTl gene was subcloned as a series of deletion mutants 
in pGL2-E (Promega) (see Fig. 2). DNA manipulations were according 
to standard methods [28]. 
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2.2. Cell culture and transfections 
293 cells were maintained in DMEM (Gibco BRL) supplemented 
with 10% foetal calf serum and 2 mM L-glutamine. Cell line T5A1 is 
derived from stable transfection of the 293 cell line with the inducible 
WTl expression vector pMWT which contains a full-length WTl 
cDNA containing splice I but not splice II (WTl-KTS). Stable trans- 
fection was achieved by electroporation (200 V, 960pF) of 2 x lo6 293 
cells grown to 50% confluence with 10 pug of pMWT. Clonal selection 
of T5Al cells was carried out using culture medium further supple- 
mented with 100 @ml hygromycin B (Boehringer-Mannheim). There- 
after, T5Al cells were maintained in media containing hygromycin. 
For transient ransfections, 40 fig of each promoter construct was 
transfected into 2 x lo6 cells by electroporation, after which cells from 
each electroporation were split equally into two plates. For each elec- 
troporation, cadmium chloride was added to 1 PM to one of the dupli- 
cate plate sets, yielding samples 293’ and T5Al’. Cells were incubated 
at 37°C for 40 h and subsequently l sed and analysed for luciferase 
activity according to the manufacturer’s protocol (Promega). Plasmid 
pGL2-E was used as the negative control, and pGL2-C, which contains 
the SV40 promoter, was used as a positive control. Assays were per- 
formed at least three times, and transfection efficiencies were monitored 
by co-transfecting 10 pg of pSV#gal. 
2.3. Northern and Western blot analyses 
For Northern blots, total cellular RNA was isolated by guanidine 
thiocyanate xtraction [28] and 10 pug electrophoresed on a 1% agarose- 
37% formaldehyde RNA gel. RNA was then transferred onto Hybond- 
N’ membranes (Amersham) in 20 x SSC, and probed with a WTl 
cDNA probe. Hybridization and washing conditions were as outlined 
in section 2.1. 
Cellular proteins for Western blot analysis were prepared by lysing 
1 x 106cells in 50~1 gel loading buffer (125 mM Tris-HCl, pH 6.8, 10% 
SDS, 20% glycerol, 10% 2-mercaptoethanol, Bromophenol blue). Sam- 
ples were boiled for 3 min, electrophoresed on 10% SDS-poly- 
acrylamide gels [29] and electroblotted onto an Immobilon-P mem- 
brane (Millipore). After blocking with low-fat dry milk (5% w/v in 10 
mM Tris-HCl, pH 7.4, 150 mM NaCl), the membrane was incubated 
overnight with human WTl monoclonal antibody C-19 (Santa Cruz 
Biotechnology). The membrane was washed in 10 mM Tris-HCl, pH 
7.4, 150 mM NaCl, 0.2% v/v Tween-20, and antibody binding was 
visualized with peroxidase-conjugated swine anti-rabbit secondary an- 
tibody (Dako) and ECL reagents (Amersham). 
3. Results and discussion 
Deletion constructs from the 5’ flanking region of the 
WTl gene were assayed for promoter activity in 293 and 
T5A1 cells. Maximal promoter activity was apparent in 
sequences extending from -450 to +200, relative to the 
major transcriptional start site [23]. The basal activity of 
PEN-7 (-450 to +200), PEN-SH (-1102 to +200) and 
PEN-1.1 (-1102 to +44) was not significantly different. 
Sequences 5’ to nucleotide -450 displayed no promoter 
activity, as shown by plasmid PEN-d5 (see Fig. 2). Plas- 
mids PEN-2 to -6 exhibit a reduced level of promoter 
activity (approximately 20-50% of PEN-SH activity). 
Cellular systems expressing different levels of WTl 
were designed in order to examine the effect of WTl 
expression on transiently transfected WTl promoter- 
luciferase gene constructs (see Fig. 1). The luciferase 
assay results summarized in Fig. 2 clearly demonstrate 
that expression of high levels of WTl lead to repression 
of the WTl promoter activity of plasmids PEN-SH, 
PEN-7 and PEN-6. The activities of these plasmids 
is curtailed by approximately 40-50% in induced 
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T5Al cells (T5Al’) compared to uninduced T5Al cells 
and 293 cells. Northern and Western blot analysis (see 
Fig. 1) shows that uninduced T5Al cells express elevated 
levels of WTl mRNA and protein relative to untrans- 
fected 293 cells. This is presumably due to ‘leaky’ metal- 
lothionein promoter activity. Interestingly, this level of 
WTl expression does not appear to be sufficient for 
repression of WTl promoter activity. The promoter ac- 
tivities of PEN- 1.1 (spanning nucleotides - 1102 to +44), 
PEN-2 (nucleotides -148 to +lO), PEN-3 (nucleotides +4 
to +200) and PEN-4 (nucleotides -144 to +200), were 
not affected by WTl expression, despite containing 2-4 
EGR/WTl binding sites (see Fig. 2). 
Comparison of PEN- 1.1 with PEN-SH implicates an 
exonic region of 157 bp between the SmaI site at position 
+38 and the P.stI site at position +195 (numbering ac- 
cording to [23]) as being crucial for the autorepressive 
B 
Fig. 1. Expression of WTl mRNA (A) and WTl protein (B). Expres- 
sion of the WTl cDNA cloned in pMWT is driven by the metal- 
lothionein promoter and was induced by addition of 1 PM cadmium 
chloride to the medium (lanes 293’ and T5Al’). Northern hybridiza- 
tion with a WTl cDNA probe (A) shows the increased mRNA expres- 
sion in T5Al and T5Al’ cells relative to the 293 cells. Western blotting 
analysis (B) demonstrates the parallel increase in WTl protein 
induction. 
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Luciferase activity 
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PEN-3 I 1 
PEN-2 L_J 
PEN-7 I I 
PEN-6 I I 
PEN-4 C I 
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92 
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Fig. 2. Analysis of WTl promoter activity in cell lines 293 and T5A1. A 1.3 kb Sad-PstI fragment encompassing 1.1 kb of the S-flanking region 
and 200 bp of exon 1 was subcloned in the luciferase reporter plasmid pGL2-E (Promega) to give plasmid PEN-SH. The 5’ region of the WTl gene 
is illustrated with circles marking potential EGR/WTl DNA binding sites and asterisks marking the GC boxes (Spl) binding sites identified by DNA 
sequencing [23]. Restriction sites shown are Sac1 (Sa), Hind111 (H), PvuII (Pv), SmaI (S) and PstI (P). The flanking region cloned in PEN-SH and 
deletion constructs derived from it are shown diagramatically. Luciferase activities are expressed as percentages of the basal PEN-SH activity in 293 
effect of WTl. The DNA sequence of this region con- 
tains 2 GC boxes which may be involved in the transcrip- 
tional activation of the WTl promoter by Spl which has 
recently been demonstrated. These Spl sites also lie im- 
mediately proximal to the 2 EGR/WTl consensus bind- 
ing sites in this exonic region [23]. A similar binding site 
juxtaposition has been shown in the murine adenosine 
deaminase gene promoter [30] where expression is regu- 
lated co-ordinately by Spl (activator) and EGR (re- 
pressor). The apparent threshold effect in our studies of 
the WTl promoter, where repression does not occur in 
the uninduced TSAl cells despite their elevated WTl 
expression status relative to 293 cells, but does occur in 
induced T5Al (T5Al’) cells, suggests that competition 
at the EGRAVTl-Spl binding loci may be responsible 
for WTl-mediated autorepression. However, the pro- 
moter activity of plasmid PEN-3, which is likely to be 
mediated by Spl, is not affected by high levels of WTl 
expression. The threshold effect may therefore reflect the 
need for WTl binding to multiple sites up- and down- 
stream of the transcriptional start site in order for repres- 
sion to occur. 
Plasmids PEN-2 and PEN-1. 1 retain 3 and 5 of the 
consensus EGR/WTl binding sites upstream of the tran- 
scriptional start site, respectively, but neither exhibits the 
WTl-mediated repression apparent with PEN-SH, PEN- 
7, or PEN-6, emphasizing the requirement for sequences 
3’ of the transcriptional start site. However, PEN-4, 
which retains the exonic region and 3 upstream EGR/ 
WTl binding sites, does not display repression, indicat- 
ing that the exonic region is necessary but not sufficient 
for repression to occur. Plasmid PEN-6, which extends 
74 bp further upstream relative to PEN-4, does exhibit 
WTl-mediated repression. This data identifies 5’ sequen- 
ces also necessary for efficient repression. The additional 
sequences in PEN-6 relative to PEN-4 restore additional 
EGR/WTl consensus binding sites in the 5’ region (see 
Fig. 2). 
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The data presented emonstrate that the human WTl 
gene promoter is subject to autosuppression in cells ex- 
pressing high levels of the WTl-KTS isoform of the 
WTl protein, and that specific sequences either side of 
the transcriptional start site are critical for WTl-medi- 
ated autosuppression. Constructs containing sequences 
solely from either 5’ or 3’ of the transcriptional start site 
do not exhibit the high level of repression apparent with 
promoter constructs spanning 5’ and 3’ sequences. These 
findings, together with the high levels of WTl expression 
necessary for repression to occur, suggest that WTl 
binding at multiple 5’ and 3’ loci is required for destabil- 
ization of the transcriptional preinitiation complex. The 
transcriptional suppression of the human PDGF-A gene 
has recently been shown to require 5’ and 3’ binding sites 
relative to the transcriptional initiation site [20]. 
During the preparation of this manuscript, negative 
autoregulation of the mouse WTl promoter was also 
reported [3 11, all isoforms of the WTl protein exhibiting 
transcriptional suppressor activity. Deletions of the re- 
gion immediately downstream of the transcriptional 
start site were shown to affect a similar loss of repression, 
mediated by a different WTl isoform (WTl+KTS) from 
the one we have studied (WTl -KTS). However, 5’ dele- 
tions were not shown to affect repression mediated by 
the WTl +KTS isoform. This may be due to the different 
WTl splice forms used and/or functional variations be- 
tween the human and mouse promoter sequences. We 
note that upstream deletions in the mouse promoter lead 
to a higher basal promoter activity whereas similar dele- 
tions curtail activity of the human promoter. 
Our studies on the human WTl promoter, together 
with those on the mouse promoter [31], illustrate the 
complexity of factors influencing the WTl promoter. In 
view of the importance of controlled WTl expression in 
normal kidney development [12], disruption of WTl 
autoregulation by promoter and/or coding sequence al- 
terations may play a key role in tumourigenesis. It will 
therefore be of interest to examine Wilms tumours for 
mutations in this region. Such studies are now underway. 
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